Dizal's Sunvozertinib Receives the NMPA’s Approval for Non-Small Cell Lung Cancer with EGFR Exon20ins Mutations
Shots:
- The NMPA has approved sunvozertinib (irreversible EGFR inhibitor) for adult patients with LA or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after Pt-based CT
- The approval was based on the (WU-KONG6) study evaluating sunvozertinib which showed a superior cORR (60.8%) at RP2D of 300mg, QD indicating an improvement over current treatment options, anti-tumor efficacy was seen across a broad range of EGFR Exon20ins subtypes, and in patients with pretreated & stable brain metastasis
- The results also showed encouraging anti-tumor activity in NSCLC patients with EGFR sensitizing, T790M & uncommon mutations as well as HER2 Exon20ins mutations, was well-tolerated with a manageable safety profile
Ref: PR Newswire | Image: Dizal
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
